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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma (NPC) is a lymphoepithelial malignancy of the nasopharynx, one of 
the etiologies is the infection of Epstein–Barr virus in undifferentiated type of nasopharyngeal carcinoma. The 
Epstein-Barr virus Nucleus Antigen-1 (EBNA-1) is Epstein–Barr virus-encoded proteins as regulatory virus 
transcription. Epithelial Growth Factor Receptor (EGFR) consist of a single polypeptide chain of amino acid, 
ErbB members, tyrosine kinase receptor, a transmembrane glycoprotein encoded by gen location in the short 
arms of a chromosome and overexpression in epithelial tumors. EGFR plays a central role in signal transduction 
pathways which regulate key cellular functions in epithelial malignancies. and may also present in NPC. 
Objective: To investigate this relation of expression patterns of EBNA-1 and EGFR in a histological type of 
undifferentiated nasopharyngeal carcinoma. 
Method: Observational, analytical study with a cross-sectional method of 34 formalin-fixed within inclusion 
criteria are   EBNA-1 and positive staining of EGFR expression (30 patients) and exclusion criteria of negative 
staining of EGFR (4 patients). All biopsy samples work with paraffin embedded and resulted in hematoxylin-
eosin undifferentiated histological types of the advanced stage in nasopharyngeal carcinoma. EBNA-1 and 
EGFR expression used immunohistochemistry staining.  
Result: EBNA-1 and EGFR expression level were detection and correlated with the advanced stadium of 
nasopharyngeal undifferentiated carcinoma. 
Conclusion: EBNA-1 is significantly related to EGFR expression in the advanced stadium of undifferentiated 
nasopharyngeal carcinoma. Overexpression of EGFR is mostly found in advanced  NPC but not in all ages. 
Male is dominated and overall age below 55 years old. Screening of EGFR with immunohistochemistry is highly 
considered before anti-EGFR treatment. 
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1. INTRODUCTION 
Nasopharyngeal carcinoma (NPC) is a head and neck malignancy 
arising from the epithelial cells of the nasopharynx it is rare in most of the 
world but common in certain geographic distribution with remarkably 
high disease incidence in southeast Asia and southern China with more 
over 50.000 new [1, 2]. Nasopharyngeal carcinoma (NPC) is squamous 
cell carcinoma which usually develops around the ostium of the 
eustachian tube in the lateral wall of the nasopharynx. While the 
environmental factors and genetic susceptibility play an important role in 
NPC pathogenesis. Over the years, many environmental and biological 
factors including tobacco, consumption of salted fish, Epstein-Barr virus 
(EBV) infection has implicated in the molecular abnormalities as well as 
genetic factors which are shown to be associated with the risk of  
Nasopharyngeal carcinoma [1, 3].  Infecting more 90% of the world 
population   EBV infections is present in all poorly and undifferentiated 
non-keratinizing NPC [3]. The primary infection can be delayed until late 
adolescence or adulthood [4]. The incidence of NPC in Indonesia cannot 
be ascertained precisely, it is because the system of recording and 
reporting has not been integrated. Several studies conducted in teaching 
hospitals estimated that the incidence in Indonesia is 6.2/100.000 
population or around 12.000 new cases per year [5]. 
 Several studies reported that about 92% of NPC are undifferentiated 
type. Epstein-Barr virus infection plays an important role in this type. 
Epstein Barr virus primary infection through the mucosal epithelium of 
the oropharynx then enters the cell cycle and releases new virion 
infections. EBNA-1 is a multifunctional protein that plays a role in the 
process of replication and the control of the episome during cell division 
in the latent phase. EBNA-1 is expressed in almost all malignancies 
associated with Epstein-Barr virus infection thus EBNA-1 is thought to 
have an important function as a regulator of protein expression and viral 
DNA replication [6, 7]. 
Epidermal growth factor receptor (EGFR) is a 170 kD transmembrane 
glycoprotein receptor with intrinsic tyrosine kinase activity regulating cell 
growth, including cell survival, differentiation, motility, and cell 
proliferation. The role of EGFR is carried out through intracellular signal 
transduction which causes cell proliferation that affecting tumor 
development [8]. Increased EGFR expression was found in more than 80% 
of patients and this was associated with regional lymph node metastasis, 
recurrence, and poor survival. Increased EGFR expression is associated 
with poor therapeutic outcomes that affect five-year survival. So that EGFR 
is thought to be the only prognosis factor that independently predicts 
recurrence and loco-regional failure that can cause death. In the study, 
Huang (2010) also found that EGFR which was expressed had a higher 
recurrence rate than unexpressed EGFR (p=0.015). Unexpressed EGFR has 
a 5-year survival and free survival which is much better overall compared 
to EGFR expressed (p=0.015; 0.013) [9]. 
Therefore, EGFR is an important factor that regulates the development 
and progression of nasopharyngeal carcinoma. However, the role and 
mechanism of EGFR in NPC has not been fully understood [10, 11]. Hence 
this study was conducted to investigate how the relation between EBNA-1 
expression and EGFR at an advanced stage of undifferentiated 
nasopharyngeal carcinoma. Overexpression of the EGFR is a hallmark of 
SCCHN (squamous cell carcinoma head and neck). High expression of 
EGFR occurs in the most epithelial malignancies including SCCHN. 
Overexpression or mutation of  EGFR is found 80-100% of the patients with 
SCCHN, and both are associated with poor prognosis and decreased survival 
[12]. Monoclonal Antibodies (mAbs) against EGFR are currently used for 
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therapy of recurrent or metastatic diseases; however, their mode of action is 
not completely understood. In the present, EFGR is considered as a primary 
target anti tumors strategies [13, 14]. 
2. MATERIAL AND METHODS 
This study was approved by the Health Research Ethics Committee of Dr. 
Soetomo Hospital. This study was an analytical observational study with a cross-
sectional design. Conducted at sub-department of oncology ENT clinic. 
Nasopharyngeal biopsy and nasopharyngeal carcinoma type examination were held 
in Anatomical Pathology laboratory Dr. Moewardi General Hospital Surakarta, 
Anatomical Pathology laboratory Medical Faculty of Sebelas Maret University and 
Kalbe genomic for staining and interpreting of EBNA-1 and EGFR expressions 
using immunohistochemistry staining examination techniques. 
The biopsies samples were a new undifferentiated patient with the 
advanced stadium of nasopharyngeal carcinoma based on AJCC/UICC. The 
study was conducted from March 2018 until the sample size was fulfilled until 
August 2018. There were 34 study samples divided with inclusion and 
exclusion criteria. The Inclusion criterion was the overexpression EGFR. 
EBNA-1 expression was examined by using Mouse Monoclonal (IgG1) to 
Epstein-Barr Virus EBV EBNA-1 R and calculated by immunohistochemistry 
using an "Allred" score [15]. (table 1), EGFR expression was examined using 
Rabbit Polyclonal to Human EGFR and calculated, immunohistochemistry 
used immunohistochemistry examination scores (table 2) [16]. 
Table 1. Score "Allred"=Proportion score+Intensity of EBNA -1 
The Percentage of  
Score 
Intensity 
Score 
Total 
Staining cell  Score 
No staining        0 No staining 0 0 
<1% 1 weak 1 2 
  1%-10% 2 moderate 2 3 
11%-33% 3 strong 3 4 
34%-66% 4   5 
67%-100% 5   6 
    7 
    8 
0-2: Negative >3: Positive  
Table 2. Immunohistology Score=Proportion score/Intensity of EGFR 
3. RESULT 
The biopsies number of 34 samples from paraffin blocks embedded 
were performed with hematoxylin eosin (HE) with undifferentiated 
nasopharyngeal carcinoma before immunohistochemistry examination.   
Table 3. The study subject characteristics 
In this study, it was showed that the mean age of patients with 
advanced stage of undifferentiated nasopharyngeal carcinoma was 55.67 
years old with the youngest age of 42 y.o and the oldest age of 77 y.o. The 
research subject who had the youngest age was 42 years, and the oldest 
was 77 years old. In this study, NPC was predominant in male (82.35%). 
All samples underwent hematoxylin eosin staining, revealing 
undifferentiated carcinoma of nasopharyngeal cancer (100%) before 
continuing with immunohistochemistry procedure, four samples had been 
excluding with negative staining. 
 
 
Table 4. The characteristics of the advanced stage of undifferentiated 
nasopharyngeal carcinoma 
The majority of the study subjects had the expression of EBNA-1 of 
70%, while EBNA-1 which was not expressed was 30%. Meanwhile, the 
measurement of EFGR variables for all study subjects was found that most 
of the study subjects had strong expression of EFGR (+3) which was 
66.67%. Most of the other research subjects had moderate expression EFGR 
(+2) which was 23.33%, and the rest were research subjects with a weak 
expressed EFGR (+1) which was 10% of all the subjects in the advanced 
stage of undifferentiated nasopharyngeal carcinoma. 
 
Picture 1. EBNA-1 expression from immunohistochemistry staining 
(Allred score), (A) negative scoring and (B) positive scoring 
  
  
  
Picture 2. Hematoxilyne Eosin (HE) and Immunohistochemistry (IHC) 
staining EGFR expression from undifferentiated carcinoma advanced 
stadium (proportion score).  
 (A) Undifferentiated carcinoma (HE), (B) negative staining, (C) weak 
staining (+), (D) intermediated staining (++), (E) strong staining (+++) with 
Immunostaining Immunohistochemistry. 
Percentage Proportion/Intensity Score 
0 Negative ( no staining of the cell membrane or staining of the 
membrane in 10% or less of the tumor cells) 
0 
>10 % Weak (weak and partial staining of the membrane in more than 
10% of tumor cells) 
1+ 
>10  % Moderate ( moderate and complete staining of the membrane in 
more than 10% of tumor cells) 
2+ 
>10 % Strong (strong and complete staining of the membrane in more 
than 10% of tumor cells)  
3+ 
Variable Descriptive value Precentage 
Grouping of age   
41-50 7 20.58% 
51-60 16 47.05% 
61-70 10 29.42% 
>70 1 2.94% 
Gender   
Male 28 82.35% 
Female 6 17.64% 
Variable 
Descriptive value 
n % 
EBNA-1 (Allred Score)   
Neg 9 30% 
Pos 21 70% 
EFGR (Score IHC)   
 +1 3 10% 
 +2 7 23.33% 
 +3 20 66.67% 
  
A 
A 
C 
B 
B 
C D 
E 
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3.1 The relation between the expression of EBNA-1 and advanced 
stage of undifferentiated nasopharyngeal carcinoma. 
Table 5. The relation of expression EBNA-1 and advanced stage of 
undifferentiated nasopharyngeal carcinoma. 
*p-value: p=0.048 (p<0.05); r=0.372 
 EBNA-1 expression founding negative on stage III is 20%, stage IV by 
10%, whereas EBNA-1 positive expression on stage III is 20% and at stage 
IV by 50%. There is a relationship among EBNA-1 expression and an 
advanced stage of undifferentiated nasopharyngeal carcinoma with a 
statistical value of; p=0.048; r=0.372 (p<0.05). 
3.2 The relation between EGFR expression and advanced stage of 
undifferentiated nasopharyngeal carcinoma 
Table 6. The relation of EGFR expression and advanced stage of 
undifferentiated nasopharyngeal carcinoma connection.  
Low expression of EGFR (+1) in stage III by 6.66% and at stage IV by 
3.34%. EGFR was moderately expressed (+2) in stage III by 16.67% and in 
stage IV by 6.66%; whereas EGFR was strongly expressed (+3) in stage III 
by 16.67% and at stage IV by 50%. There is a connection among EGFR 
expression with advanced stage undifferentiated nasopharyngeal carcinoma 
with a statistical value of; p=0.021; r=0.421 (p<0.05).  
3.3 The relation between EBNA-1 and EGFR expression in the 
advanced stage of undifferentiated nasopharyngeal carcinoma 
Table 7. The EBNA-1 and EGFR expression in stage III of 
undifferentiated nasopharyngeal carcinoma 
*p-value: p=0.022 (p<0.05); r=0.652 
In stage III of undifferentiated nasopharyngeal carcinoma (12 patients) had 
low expression of EGFR (+1) in negative, EBNA-1 expression 8.33%, positive 
EBNA-1 expression was 8.33%. The Moderate EGFR expression (+2) was in 
negative EBNA-1 expression (41.67%) and strong EGFR expression (+3) on 
EBNA-1 expression positive 41.67%. There was a relation between EBNA-1 
expression and EGFR in stage III undifferentiated nasopharyngeal carcinoma 
with statistical value of  p=0.022; r=0.652 (p <0.05).  
Table 8. The relation between EBNA-1 and EGFR expression in stage IV 
undifferentiated nasopharyngeal carcinoma. 
*p-value: p=0.00 (p<0.05); r=0.996 
 
The undifferentiated nasopharyngeal carcinoma on stage IV, 18 patients 
with low EGFR (+1) in negative EBNA-1 expression are 5.56%. Moderate 
expression of EGFR (+2) in negative EBNA-1 expression is 11.11%, and strong 
expression of EGFR (+3) in EBNA-1 positive expression was 83.33%. The 
correlation between the expression of EBNA-1 and EGFR on stage IV 
undifferentiated nasopharyngeal carcinoma obtained statistical value of; p= 0.00; 
r=0.996 (p<0.05). The general result, there is a connection among EBNA-1 and 
EGFR expression in the advanced stage IV of undifferentiated nasopharyngeal 
carcinoma with a statistical value of p=0.000; r=0.774 (p<0.05). 
4. DISCUSSION 
The findings are consistent with previous epidemiological studies, 
Adham et.al. which reported that the distribution of nasopharyngeal 
carcinoma patients was more dominant in men, with a male: female ratio of 
70.4%:29.6%, while the highest average age was in the 41-50 year with a 
percentage of 32.4%,  the youngest age <21 years was equal to 9.9% and 
the oldest age >70 years was 1.9% [17]. Other studies which were conducted 
in various countries outside Indonesia found similar results, Mak conducted 
a cohort study on 558 patients with nasopharyngeal carcinoma obtained a 
ratio of male: female by 73.3%: 26.7%, with an average age of the patients, 
was 51.8 years with the youngest age of 14 years and the oldest age of 94 
years [18]. Another study showed a comparison of male: female 
nasopharyngeal carcinoma patients by 82.6%:17.4%, with a median age of 
the research subject was 50 years. Chen from his study of 530 
nasopharyngeal carcinoma patients, obtained a ratio of male:female by 
74.34%:25.66%, with an average age of the research subject was 44 years, 
with the youngest age was 16 years, and the oldest age was 79 years [19]. 
Thus it can be said that most of the patients with an advanced stage of 
undifferentiated nasopharyngeal carcinoma are men. This is probably due to 
carcinogenic substances exposure such as cigarette smoke, alcohol 
consumption, and other carcinogenic substances. Based on the age of the 
patient, an advanced stage of undifferentiated nasopharyngeal carcinoma is 
more often in adulthood, this is due to being a carcinoma requires time to 
develop into an advanced stage.  
In this study expressed EBNA-1 was found at 70% from the advanced 
stadium, while unexpressed EBNA-1 was found at 30%. This is in line with 
previous studies, Lao, 2017 conducted a study on 31 nasopharyngeal 
carcinomas biopsied tissue, EBNA-1 expression was calculated using the 
same technique (immunohistochemistry) obtaining 77.42% expressed 
EBNA-1, whereas in healthy nasopharyngeal tissue were not EBNA-1 
expression. Borthakur obtained the results of EBNA-1 expression in  
nasopharyngeal carcinoma by 92.5%. Xiao et al., conducted a study of 
the expression of EBNA-1 in all types of nasopharyngeal carcinoma and 
obtained 79.5% EBNA-1 expression [11]. 
EBNA-1 expression was associated with an advanced stage of 
undifferentiated nasopharyngeal carcinoma (p=0.048; r=0.372 (p<0.05). 
This shows that EBNA-1 is a protein expressed in all latent phases due to 
Epstein-Barr virus infection. EBNA-1 as a multifunctional protein that 
relates to the process of replication and control of the episome during cell 
division. EBNA-1 has a variety of strain which is the specific, stable and 
long half-life of the translation process to mRNA. The role of EBNA-1 
primarily increases TGF-β regulation which resulting in an increase in cell 
proliferation in undifferentiated nasopharyngeal carcinoma. EBNA-1 
activity is carried out by activating the Akt pathway (through β-catenin 
upregulation), ERK (through upregulation of NFκ-B, AP-1)  to increase cell 
proliferation. EBNA-1 also acts as an E-Cadherin up regulator, so that the 
tumor can invade. EBNA-1 can initiate the transition of nasopharyngeal 
carcinoma epithelial cells and promote nasopharyngeal carcinoma cells to 
migrate and to invade surrounding cells. Noh (2016) in his study proved the 
inhibition of ERK could cause suppression of EBNA-1 function, this finding 
proved the role of  EBNA-1 in the activation of the EBNA-1 signaling 
pathway through upregulation of the ERK pathway [20]. Wang obtained 
87.5% EBNA-1 expression in nasopharyngeal carcinoma biopsy tissue, and 
EBNA-1 expression was related to tumor stage (p=0.000), pathological 
stage (p=0.018) in undifferentiated type, and EBNA expression -1 is 
associated with regional lymph node metastasis (p=0.003). This is also in 
line with this study, found an association between EBNA-1 expression was 
associated with the clinical stage (clinical stage/T) (p=0.00; r=0.769) 
regional neck lymph node enlargement (p=0.000; r=0.749) [20]. 
The expression of EBNA-1 in NPC tissue resembles the role of Epstein-
Barr virus infection in patients with nasopharyngeal carcinoma. In this study, 
not all patients with advanced stage of undifferentiated nasopharyngeal 
carcinoma expressed EBNA-1, several factors may contribute to this finding, 
Variable 
Advanced stage of nasopharyngeal 
III  IV  Total 
EBNA-1  n             % n            % n             % 
-  6 20% 3 10% 9 30% 
+  6 20% 15 50% 21 70% 
Total 12 40% 18 60% 30 100% 
Variable  
Advanced stage of nasopharyngeal cancer 
III  IV  Total 
EGFR  n                    % n                % n                % 
+1  2 6.66% 1    3.34% 3 10% 
+2  5 16.67% 2 6.66% 7 23.33% 
+3  5 16.67% 15 50% 20 66.67% 
Total 12 40% 18 60% 30 100% 
Variable 
EBNA-1 
Negative   Positive  Total 
EGFR n                    % n               % n             % 
+1  1 8.33% 1 8.33% 2 16.66% 
+2  5 41.67% 0 0% 5 41.67% 
+3  0 0% 5 41.67% 5 41.67% 
Total 6 50% 6 50% 12 100% 
Variable  
EBNA-1 
Negative  Positive  Total 
EGFR n                 % n              % n            % 
+1  1 5.56% 0 0% 1 5.56% 
+2  2 11.11% 0 0% 2 11.11% 
+3  0 0% 15 83.33% 15 83.33% 
Total 3 16.67% 15 83.33% 18 100% 
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such as undifferentiated nasopharyngeal carcinoma include the type of 
examination used the specificity and sensitivity of the reagents, equipment as 
well as  the method of calculating the results [21]. 
EFGR in this study was strongly expressed (+3) which is equal to 
66.67% and EFGR (+1) expression was 10%, and no negative EGFR 
expression was found. Previous studies, Liu (2015) obtained an expressed 
EGFR of 89.5% and it was associated with tumor expansion and the 
presence of regional neck lymph node enlargement, Yang reported 89.5% of 
EGFR expression, and its association with the spread around the tumor (T) 
and regional lymph node enlargement (N) [22]. EGFR expression plays an 
important role in nasopharyngeal carcinoma; thus it is often referred to as 
an independent factor in the development of nasopharyngeal carcinoma [8]. 
In the normal epithelium, there is a balance of cellular differentiation and 
well-controlled cellular proliferation. In epithelial malignancies as in 
nasopharyngeal carcinoma, uncontrolled growth is mediated by EGFR. 
Increased EGFR expression in tumor cells will cause tumors to develop, a 
process of tumor invasion by 60 percent and EGFR expression associated 
with poor clinical outcomes. Resulting in increased cell proliferation and 
regional lymph node metastases [23, 24]. 
Increased EGFR expression causes activation of the PKC pathway 
(with increasing STAT3), PI3K pathway (with increasing Cyclin E) leading 
to increased cell proliferation. Zhang in his study reported that EGFR 
expression related to the clinical stage of tumor T (p=0.005) and that EGFR 
expression associated with advanced stages (p=0.001). Pan (2013) mentions 
EGFR plays a role in STAT3 upregulation, in which increased STAT3 will 
increase the expression of cyclin-D1 and cMyc which then regulates the G1 
phase in the cell cycle so that the cell cycle continuously progresses and the 
tumor develops [25]. STAT3 also enhances the formation of regional lymph 
node enlargement. This is in accordance with this study, it was found an 
association between EGFR expression with clinical stage (clinical stage/T) 
(clinical stage/T) (p=0.000; r=0.860) and associated regional lymph node 
metastases (p=0.000; r=0.795). 
 Immunohistochemistry (IHC) protocols use monoclonal antibodies of EGFR 
on paraffin specimens sliced on a microtome. The main indication of IHC is a 
definition on histogenesis, differential diagnosis between reactive and neoplastic 
states, etiologic diagnosis of infectious disease, determination of prognosis factor, 
determination of target therapy sites, the location of primary tumors in malignant 
disease, determination of specific products (such as hormones and protein and 
cancer subtyping) [26]. IHC has played a significant role in primary tumor site 
identification in metastatic disease. Panels labeling Squamous cell carcinoma, 
adenocarcinoma, thyroid carcinoma, sarcoma, lymphoma, neuroendocrine 
carcinoma, and melanoma can improve diagnostic accuracy and thus provide 
valuable input to the determination of the most effective course of therapy.                         
The technique helps in screening head and neck tumors, mainly in diagnosing 
sarcomas and lymphomas and enabling their adequate classification [26]. 
Immunohistochemistry has significantly improved the outlook for pathology test. 
The study have shown overexpression of EGFR only in the advanced stage but not 
in the early stage of NPC from IHC score.   
The author cannot find subjects with the advanced stage of 
undifferentiated nasopharyngeal carcinoma had EGFR expression. This 
may be in the form of errors in sample collection, techniques for examining 
EGFR expression, interpretation of the results of immunohistochemistry 
examinations (semi-quantitative examination techniques are very dependent 
on the examiner's ability) so that they can influence the expression results. 
EBNA-1 is a multifunctional protein which plays a role in the process of 
replication and control of the episome during cell division in the latent 
phase. EBNA-1 is expressed in almost all malignancies associated with 
Epstein-Barr virus infection so that EBNA-1 has an important function as a 
regulator of protein expression and viral DNA replication. EGFR, which is 
a receptor on the cell membrane, is a growth factor receptor that regulates 
basic cell behavior including cell survival, differentiation, motility, and 
proliferation. EBNA-1 influence EGFR expression at an advanced stage of 
undifferentiated nasopharyngeal carcinoma. Overexpression of EGFR is 
potential for targeted therapy with the anti-EGFR antibody. IHC showed that 
immunohistochemical staining for specific EGFR antibodies are a reliable 
source for diagnostic of mutation and confirming previous reports [27].             
The recent study proposed of EGFR to be used as a predictor and prognostic 
factor for a new generation in NPC therapy with anti-EGFR. 
5. CONCLUSION 
The findings are consistent with previous epidemiological studies, 
Adham et.al,. which reported that the distribution of nasopharyngeal 
carcinoma patients was more dominant in men, with male:female ratio of 
70.4%:29.6%, while the highest average age was in the 41-50 year with a 
percentage of 32.4%,  the youngest age <21 years was equal to 9.9% and 
the oldest age >70 years was 1.9% [5]. Other studies which were conducted 
in various countries outside Indonesia found similar results, Mak conducted 
a cohort study on 558 patients with nasopharyngeal carcinoma obtained a 
ratio of male: female by 73.3%:26.7%, with an average age of the patients, 
was 51.8 years with the youngest age of 14 years and the oldest age of 94 
years [18]. Another study showed a comparison of male: female 
nasopharyngeal carcinoma patients by 82.6%: 17.4%, with a median age of 
the research subject was 50 years. Chen from his study of 530 
nasopharyngeal carcinoma patients, obtained a ratio of male:female by 
74.34%:25.66%, with an average age of the research subject was 44 years, 
with the youngest age was 16 years, and the oldest age was 79 years [19]. 
Thus it can be said that most of the patients with an advanced stage of 
undifferentiated nasopharyngeal carcinoma are men. This is probably due to 
carcinogenic substances exposure such as cigarette smoke, alcohol 
consumption, and other carcinogenic substances. Based on the age of the 
patient, an advanced stage of undifferentiated nasopharyngeal carcinoma is 
more often in adulthood, this is due to being a carcinoma requires time to 
develop into an advanced stage. 
 In this study expressed EBNA-1 was found at 70% from the advanced 
stadium, while unexpressed EBNA-1 was found at 30%. This is in line with 
previous studies, Lao, 2017 conducted a study on 31 nasopharyngeal 
carcinomas biopsied tissue, EBNA-1 expression was calculated using the 
same technique (immunohistochemistry) obtaining 77.42% expressed 
EBNA-1, whereas in healthy nasopharyngeal tissue were not EBNA-1 
expression. Borthakur obtained the results of EBNA-1 expression in 
nasopharyngeal carcinoma by 92.5%. Xiao et al., conducted a study of the 
expression of EBNA-1 in all types of nasopharyngeal carcinoma and 
obtained 79.5% EBNA-1 expression [11]. 
EBNA-1 expression was associated with an advanced stage of 
undifferentiated nasopharyngeal carcinoma (p=0.048; r=0.372 (p<0.05). 
This shows that EBNA-1 is a protein expressed in all latent phases due to 
Epstein-Barr virus infection. EBNA-1 as a multifunctional protein that 
relates to the process of replication and control of the episome during cell 
division. EBNA-1 has a variety of strain which is the specific, stable and 
long half-life of the translation process to mRNA. The role of EBNA-1 
primarily increases TGF-β regulation which resulting in an increase in cell 
proliferation in undifferentiated nasopharyngeal carcinoma.EBNA-1 
activity is carried out by activating the Akt pathway (through β-catenin 
upregulation), ERK (through upregulation of NFκ-B, AP-1)  to increase cell 
proliferation. EBNA-1 also acts as an E-Cadherin up regulator, so that the 
tumor can invade. EBNA-1 can initiate the transition of nasopharyngeal 
carcinoma epithelial cells and promote nasopharyngeal carcinoma cells to 
migrate and to invade surrounding cells. Noh (2016) in his study proved the 
inhibition of ERK could cause suppression of EBNA-1 function, this finding 
proved the role of EBNA-1 in the activation of the EBNA-1 signaling 
pathway through upregulation of the ERK pathway [20]. Wang obtained 
87.5% EBNA-1 expression in nasopharyngeal carcinoma biopsy tissue, and 
EBNA-1 expression was related to tumor stage (p=0.000), pathological 
stage (p=0.018) in undifferentiated type, and EBNA expression -1 is 
associated with regional lymph node metastasis (p=0.003). This is also in 
line with this study, found an association between EBNA-1 expression was 
associated with the clinical stage (clinical stage/T) (p=0.00; r=0.769) 
regional neck lymph node enlargement (p=0.000; r=0.749) [6]. 
The expression of EBNA-1 in NPC tissue resembles the role of Epstein-Barr 
virus infection in patients with nasopharyngeal carcinoma. In this study, not all 
patients with advanced stage of undifferentiated nasopharyngeal carcinoma 
expressed EBNA-1, several factors may contribute to this finding, such as 
undifferentiated nasopharyngeal carcinoma include the type of examination used 
the specificity and sensitivity of the reagents, equipment as well as  the method 
of calculating the results [21]. 
EFGR in this study was strongly expressed (+3) which is equal to 
66.67% and EFGR (+1) expression was 10%, and no negative EGFR 
expression was found. Previous studies, Liu (2015) obtained an expressed 
EGFR of 89.5% and it was associated with tumor expansion and the 
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presence of regional neck lymph node enlargement, Yang reported 89.5% of 
EGFR expression, and its association with the spread around the tumor (T) 
and regional lymph node enlargement (N) [22]. EGFR expression plays an 
important role in nasopharyngeal carcinoma; thus it is often referred to as 
an independent factor in the development of nasopharyngeal carcinoma [8]. 
In the normal epithelium, there is a balance of cellular differentiation and 
well-controlled cellular proliferation. In epithelial malignancies as in 
nasopharyngeal carcinoma, uncontrolled growth is mediated by EGFR. 
Increased EGFR expression in tumor cells will cause tumors to develop, a 
process of tumor invasion by 60 percent and EGFR expression associated 
with poor clinical outcomes. Resulting in increased cell proliferation and 
regional lymph node metastases [23, 24]. 
Increased EGFR expression causes activation of the PKC pathway 
(with increasing STAT3), PI3K pathway (with increasing Cyclin E) leading 
to increased cell proliferation. Zhang in his study reported that EGFR 
expression related to the clinical stage of tumor T (p=0.005) and that EGFR 
expression associated with advanced stages (p=0.001). Pan (2013) mentions 
EGFR plays a role in STAT3 upregulation, in which increased STAT3 will 
increase the expression of cyclin-D1 and cMyc which then regulates the G1 
phase in the cell cycle so that the cell cycle continuously progresses and the 
tumor develops [25]. STAT3 also enhances the formation of regional lymph 
node enlargement. This is in accordance with this study, it was found an 
association between EGFR expression with clinical stage (clinical stage/T) 
(clinical stage/T) (p=0.000; r=0.860) and associated regional lymph node 
metastases (p=0.000; r=0.795). 
Immunohistochemistry (IHC) protocols use monoclonal antibodies of 
EGFR on paraffin specimens sliced on a microtome. The main indication of IHC 
is a definition on histogenesis, differential diagnosis between reactive and 
neoplastic states, etiologic diagnosis of infectious disease, determination of 
prognosis factor, determination of target therapy sites, the location of primary 
tumors in malignant disease, determination of specific products (such as 
hormones and protein and cancer subtyping) [26]. IHC has played a significant 
role in primary tumor site identification in metastatic disease. Panels labeling 
Squamous cell carcinoma, adenocarcinoma, thyroid carcinoma, sarcoma, 
lymphoma, neuroendocrine carcinoma, and melanoma can improve diagnostic 
accuracy and thus provide valuable input to the determination of the most 
effective course of therapy. The technique helps in screening head and neck 
tumors, mainly in diagnosing sarcomas and lymphomas and enabling their 
adequate classification [26]. Immunohistochemistry has significantly improved 
the outlook for pathology test. This study have shown overexpression of EGFR 
only in the advanced stage but not in the early stage of NPC from IHC score.  
The author did not find subjects with the advanced stage of 
undifferentiated nasopharyngeal carcinoma had EGFR expression. This 
may be in the form of errors in sample collection, techniques for examining 
EGFR expression, interpretation of the results of immunohistochemistry 
examinations (semi-quantitative examination techniques are very dependent 
on the examiner's ability) so that they can influence the expression results. 
EBNA-1 is a multifunctional protein which plays a role in the process of 
replication and control of the episome during cell division in the latent 
phase. EBNA-1 is expressed in almost all malignancies associated with 
Epstein-Barr virus infection so that EBNA-1 has an important function as a 
regulator of protein expression and viral DNA replication. EGFR, which is 
a receptor on the cell membrane, is a growth factor receptor that regulates 
basic cell behavior including cell survival, differentiation, motility, and 
proliferation. EBNA-1 influence EGFR expression at an advanced stage of 
undifferentiated nasopharyngeal carcinoma. Overexpression of EGFR is 
potential for targeted therapy with the anti-EGFR antibody. IHC showed that 
immunohistochemical staining for specific EGFR antibodies are a reliable 
source for diagnostic of mutation and confirming previous reports.               
The recent study proposed of EGFR to be used as a predictor and prognostic 
factor for a new generation in NPC therapy with anti-EGFR.  
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